IMMUCOR SEES FLAT EARNINGS FOR FISCAL YEAR
IMMUCOR SEES FLAT EARNINGS FOR FISCAL YEAR NORCROSS, Ga., July 2 /PRNewswire/ -- Immucor, Inc.
(NASDAQ-NMS: BLUD), maker of blood bank reagent systems and related products, announced today the company expects to report a decline in fourth quarter earnings, and flat year-end earnings, as compared to the same periods last year.
"Our year-end audit is in process, and final results will not be available for several weeks. However, based upon preliminary information, we see a decline in fourth quarter net income of approximately 20-25 percent as compared to a year ago," said Edward L. Gallup, president of Immucor. "As a result, year-end net income is expected to be approximately equal to last year's $3.1 million, with earnings per share around 10 percent less than last year's $.38, due to an increase in the weighted average number of common shares and common share equivalents." Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used primarily by hospitals and blood banks in a number of tests performed to detect and identify certain properties of the cell and serum components of human blood prior to blood transfusion. Through its German and Italian subsidiaries, the company also sells blood bags for the collection, storage and administration of human blood, HLA products used primarily in human organ transplantation, DNA probes used in paternity testing and forensic medicine, and tests for certain infectious diseases. -0- 7/2/92 /CONTACT: Richard J. Still, senior vice president - Finance of Immucor, 404-441-2051/ (BLUD) CO: Immucor, Inc. ST: Georgia IN: MTC SU: ERP
BN-CF -- AT002 -- 6005 07/02/92 07:59 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 2, 1992|
|Previous Article:||LEAR SEATS IN 1 MILLIONTH CORVETTE|
|Next Article:||NEW JERSEY'S HEALTH CARE CRISIS FOCUS FOR CABLE SPECIAL|